According to the Izvestia publication, domesticresearchers from the Institute of Organic Chemistry named after N. D. Zelinsky, Institute of Development Biology. N.K. Koltsova and the foreign company Immune Pharmaceuticals, under the guidance of MIPT professor Alexander Kiselev, managed to obtain a substance that can destroy chemotherapy-resistant tumors. The antitumor activity of the compound was effective even for one of the most resistant types of human cancer - ovarian carcinoma.
During clinical trials, scientists were37 chemical compounds belonging to the class of aminothiazoles have been developed. 12 of them slow down and completely stop the division of tumor cells. The drug acts at the cellular level on microtubes, consisting of tubulin protein. These microtubes direct elements of dividing cells during mitosis. Thus, cancer cells lose their ability to divide, after which the tumor dies. According to project manager Alexander Kiselev,
“The choice of the class of compounds is not accidental. The fact is that many aminothiazoles exhibit a wide range of pharmacological and biological activity. Therefore, we hypothesized that compounds of this class with the appropriate chemical groups may exhibit anticancer activity. The substance is not toxic to sea urchins, which means there is the potential for research on animals. The study can be used to create therapies for general and resistant ovarian cancer. The development of drugs is a long and strictly regulated process, but with successful trials, it can be expected that trials on patients will take place in 1.5–2 years. ”
Antitumor Activity Testswere carried out both in vivo - in a living organism of sea urchins, and in vitro - in vitro on a substrate from cells of prostate cancer, breast adenocarcinoma, melanoma and lung cancer. The process of cell division in ovarian cancer, the connection was completely stopped. But in the case of other tumor processes, only a significant slowdown was observed. Although it is not yet possible to speak about the introduction of the drug into medical practice, scientists are already planning to conduct structural modeling of microtubule destruction in order to determine the binding sites of the compound with the tubulin protein, which will contribute to improving the mechanism of action of the future drug. According to the deputy director of the Russian Cancer Research Center. N. N. Blokhin David Zaridze,
“This is an important, but very initial stage, which inperspective can lead to the invention of new drugs. It is good that positive results have been obtained now, but studies on experimental animals and sick people still have to be done. In general, in most cases, the tumor is initially sensitive to chemotherapy, that is, it responds positively to treatment, but after the course becomes stable, the sensitivity almost always decreases, so the search for compounds that help fight a resistant tumor is an important process. ”